GSK Reports Results from the P-III (EAGLE-1) Study of Gepotidacin for the Treatment of Urogenital Gonorrhoea (GC)
Shots:
- The P-III (EAGLE-1) study compares the safety & efficacy of gepotidacin vs ceftriaxone + azithromycin for treating adults & adolescents (n=600) with uncomplicated urogenital gonorrhoea
- The study’s 1EP, the microbiological response at the ToC visit 3-7 days after treatment, depicted gepotidacin's (oral, two doses of 3,000mg) non-inferiority to ceftriaxone (500mg, IM) + azithromycin (1,000mg, oral) for urogenital gonorrhea
- Gepotidacin is a bactericidal antibiotic that hinders bacterial DNA replication & inhibits two different Type II topoisomerase enzymes for most pathogens. It is also being evaluated for treating uncomplicated urinary tract infections (uUTI)
Ref: GSK | Image: GSK
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
